The accumulation of somatic mutations in a genome is the result of the activity of one or 15 more mutagenic processes, each of which leaves its own imprint. The study of these DNA 16 fingerprints, termed mutational signatures, holds important potential for furthering our 17 understanding of the causes and evolution of cancer, and can provide insights of relevance for 18 cancer prevention and treatment. In this review, we focus our attention on the mathematical 19 models and computational techniques that have driven recent advances in the field. 20 21
Introduction 24
Cancer is a disease of the genome, in which uncontrolled clonal proliferation is initiated and 25 fuelled by genomic alterations in somatic cells [1] . Despite the fact that a cancer genome may 26 carry between tens and millions of somatic mutations [2, 3] , only a small subset of these,termed 'driver' mutations, are thought to be under selection and to cause neoplastic expansion 28 [1, 4] . The remaining 'passenger' mutations are generally believed not to confer selective 29 advantage, and to arise from the processes involved in mutagenesis [5, 6] . The collection of 30 mutations in a somatic cell genome is the result of one or more mutational processes 31 operating, continuously or intermittently, during the organism's lifetime [7] . Such mutational 32 processes include DNA damage by exogenous or endogenous agents, defective DNA 33 replication, insertion of transposable elements, defects in DNA repair mechanisms, and 34 enzymatic modifications of DNA, among others [8] . Many of these processes imprint a 35 distinct pattern of mutations in the genome, known as a 'mutational signature' [2, 9] . 36 Therefore, the compendium of somatic changes in a cancer genome constitutes a record of the 37 combined mutagenic effect of the specific mixture of processes moulding it [2] . Furthermore, 38 because most mutations are passengers, they are largely beyond the effect of adaptive 39 selection [10] . 40
Although mutational signatures are a relatively recent concept in cancer biology, the 41 first descriptions of genomic aberrations caused by a specific process date back to the early 42 twentieth century, when X-rays were found to induce chromosome breakage in irradiated 43 cells [11] [12] [13] . More-detailed mutational patterns were reported in the 1960s, notably the 44 crosslinking of adjacent pyrimidine bases (CC, CT, TC, TT) due to ultraviolet radiation, 45 which produces cytosine-to-thymine (C>T) and cytosine-cytosine-to-thymine-thymine 46 (CC>TT) transitions at dipyrimidine sites [14] [15] [16] . Other causal links between mutagenic 47 agents and patterns of somatic changes have also become established, such as the guanine-to-48 thymine (G>T) transversions resulting from guanine adducts that are caused by carcinogens 49 present in tobacco smoke [17, 18] . Furthermore, some chemotherapeutic agents are mutagens 50 as well, and may imprint their own mutational signature in the cancer genomes of patients 51 with secondary malignancies [19, 20] . These examples illustrate the importance of studying 52 somatic mutation patterns to our understanding of the molecular mechanisms of neoplasia, 53 potentially enabling the discovery of novel mutagens [2, 7, 8, 21] . Moreover, several authorshave emphasised the potential of mutational signature analysis to provide insights of clinical 55 significance, by informing and guiding diagnostic procedures, personalised cancer 56 interventions and prevention efforts [19, [22] [23] [24] [25] [26] [27] . 57 as biological constraints for the identification of signatures, even if precisely modelling them 82
These features make NMF especially well-suited to the problem of mutational signature 150 inference, because of the intrinsic nonnegativity of the matrices in the mathematical model 151 presented above. Moreover, NMF has repeatedly stood out as a powerful technique for the 152 extraction of meaningful components from various types of high-dimensional biological data 153 [38] [39] [40] [41] [42] , besides successful applications in other fields [39] . 154 NMF constituted the basis of the first computational method for mutational signature 155 inference, the Wellcome Trust Sanger Institute (WTSI) Mutational Signature 156
Framework (hereafter referred to as the WTSI Framework). This was published, together 157 with the mathematical model introduced above, in a landmark work by Alexandrov et al. 158 [34], which enabled the first detailed delineations of mutational signatures in human cancer 159
[2, 33, 43] . The WTSI Framework performs NMF on a set of mutational catalogues by 160 building upon an implementation, developed by Brunet et al. [38] , of the multiplicative 161 update algorithm devised by Lee and Seung [36, 44] . More formally, given a set of mutational 162 catalogues, M, composed of G genomes defined over K mutation types, the method extracts 163 exactly N mutational signatures (with 1 ≤ N ≤ min{K, G} -1), by finding the matrices S and 164
E that approximately solve the nonconvex optimisation problem derived from (4), with the 165 selected matrix norm being the Frobenius reconstruction error: 166
The algorithm first initialises S and E as random nonnegative matrices, and reduces 167 the dimension of M by removing those mutation types that together account for ≤1% of all the 168 mutations. Two steps are then iteratively followed: (a) Monte Carlo bootstrap resampling of 169 the reduced catalogue matrix, and (b) application of the multiplicative update algorithm to the 170 resampled matrix, finding the instances of S and E that minimise the Frobenius norm in (5). 171
After completion of the iterative stage, partition clustering is applied to the resulting set of 172 signatures, in order to structure the data into N clusters. The N consensus signature vectors, 173 which compose the averaged signature matrix, S, are obtained by averaging the signatures in 174 each cluster. Since each signature is related to a specific exposure, the averaged exposurematrix, E, can be inferred from S. In cases where the mutational catalogues have been derived 176 from cancer exomes, the extracted mutational signatures should thereafter be normalised to 177 the trinucleotide frequencies of the whole genome. 178
The WTSI Framework requires the number of signatures to infer, N, to be defined as 179 a parameter. Because the number of signatures present in the data is normally not known a 180 priori, the framework needs to be applied for values of N ranging between 1 (or the smallest 181 plausible number of signatures) and min{K, G} -1. For each value of N, the overall 182 reproducibility (measured as the average silhouette width [45] of the signature clusters, using 183 cosine similarity) and Frobenius reconstruction error are calculated, and the best value is 184 selected such that the resulting signatures are highly reproducible and exhibit low overall 185 reconstruction error. Nevertheless, the manual determination of N on the basis of these 186 criteria is perhaps the most heavily criticised aspect of the WTSI Framework. Accurate 187 estimation of the number of mutational signatures, besides remaining one of the thorniest 188 facets of mutational signature analysis, is crucial given the associated risks of inferring 189 signatures that merely describe the noise in the data by overfitting (through overestimation of 190 N), or insufficiently separating signatures present in the data by underfitting (through 191
underestimation of N). 192
Although the NMF approach has proven highly effective, especially when applied to 193 large cohorts of cancer genomes, it is not without conceptual limitations [34] . The first of 194 these lies in the number of catalogues required, which is a limiting factor on the number of 195 signatures that can be accurately extracted, and rises exponentially with N. The number of 196 mutations per catalogue also influences the power to infer signatures, with a small set of 197 densely mutated genomes being more informative than a large number of sparsely mutated 198 genomes. In fact, the influence of catalogues with extreme mutation burdens (hypermutated 199 genomes) on the NMF process can hinder the detection of signals from less-mutated 200 catalogues. Furthermore, mutational signatures exhibiting higher exposures can generally be 201 identified more easily and accurately. Sensitivity to initial conditions is another majorlimitation, arising from the high dimensionality and inherent nonconvexity (presence of 203 multiple local minima) of the optimisation problem posed by (5). This aspect of NMF has 204 attracted particular attention in the past, leading to the proposal of alternative initialisation 205 strategies [46, 47] that might outperform the random initialisation adopted by the WTSI 206
Framework. 207
In more recent analyses, the WTSI working group has significantly refined their own 208 application of the WTSI Framework, in order to enhance power and accuracy; however, such 209 refinements have not been incorporated in the publically available software. Firstly, an 210 additional analysis step can follow the deconvolution of consensus mutational signatures, 211 which centres on precisely estimating the contribution of each signature to each genome [28] . 212 This is individually achieved for each catalogue through minimisation of a variation of the 213 function shown in (5); the difference lies in S now being known, and harbouring only the 214 consensus mutational patterns of the processes that operate in the tumour type of the sample 215 (these are known from the signature extraction process). Notably, additional biological 216 constraints are imposed in the selection of the processes included in S; these require that, for 217 each candidate process, at least one associated genomic feature (e.g. transcriptional strand 218 bias or enrichment in aberrations of a specific type) be present in the examined sample. The 219 second enhancement consists of a 'hierarchical signature extraction' process [29] , which is 220 directed to increase the power to identify signatures exhibiting either low activity or limited 221 representation across the sample cohort. Here, the WTSI Framework is initially applied to the 222 original matrix, M, containing all the somatic catalogues. After identification of signatures, 223 those samples that are well-explained by the resulting mutational patterns are removed from 224 M, and the method is re-applied to the remaining catalogues. The process is repeated until no 225 new signatures are discovered, and the additional step for estimating signature contributions 226 described above is then applied to all the consensus patterns. Although both SomaticSignatures and MutSpec ultimately apply the same 249 implementation of the multiplicative update algorithm for NMF [38] originally adopted by the 250 WTSI Framework, it should be noted that these packages may not produce identical results to 251 those of the latter, since they lack the computationally intensive pre-processing and 252 bootstrapping routines that complement the application of NMF in the method devised by 253
Alexandrov et al. [34] . Nevertheless, SomaticSignatures and MutSpec do adopt the definition 254 of mutational signatures as probability vectors over single-base substitution types in a 255 trinucleotide context. It is worth noting that one recent study [27] that applied both the WTSIFramework and SomaticSignatures for de novo extraction of signatures from esophageal 257 adenocarcinoma genomes reported a high similarity between the core mutational patterns 258 identified by both tools. 259
In contrast to the numerical optimisation approach to mutational signature inference 262 expressed by (5), probabilistic frameworks have also been devised which exploit the 263 intrinsically stochastic nature of mutagenesis. These frameworks have been claimed to be 264 better-suited to deal with mutational stochasticity, which is partly responsible for the noise 265 observed in mutational catalogues and becomes more prominent as less-mutated genomes, or 266 smaller genomic regions, are examined. 267
The first probabilistic approach in the field was developed by Fischer et al. [61] , Another novelty of EMu is the incorporation of tumour-specific variation in 278 mutational opportunity across different sequence contexts. Mutational opportunities, which 279 derive from the sequence composition of a genome, can be expressed as a nonnegative K-280 tuple containing the opportunity for each mutation type in the genome g, 281
For single-base substitutions in a trinucleotide context, the 282 opportunities correspond to the frequencies of each trinucleotide type in each genome.
Explicitly accounting for the opportunity for mutations to occur is especially relevant given 284 that the relative frequency of certain sequences in the human genome (e.g. 285 underrepresentation of CpG dinucleotides) can exert undesired biases on the inferred 286 mutational patterns. In addition, copy number alterations, which are frequent in cancer 287 genomes [1, 67] , can substantially alter the mutational opportunity in affected regions across 288 tumours. The divergence in sequence composition across genomic segments also makes 289 opportunity a relevant factor in the determination of signature contributions in a specific 290 region. The probabilistic framework and explicit dependence on opportunity are intended to 291 increase adaptability for the analysis of signatures in short genomic regions. 292
Fischer et al. make use of a Poisson-distributed probabilistic model to describe the 293 mutational catalogue of a given genome as the result of a stochastic process of mutation 294 accumulation. Assuming the N mutational processes to be mutually independent, the 295 probability of observing the catalogue
In this model, the mutational signatures, S, act as the shared model parameters, and 297 the signature exposures, E, as the hidden data. The end of the EM procedure is to find 298 maximum likelihood estimates of both, thereby solving the deconvolution problem. The 299 algorithm starts by making an initial guess of the model parameters, S (0) , and thereafter 300 iterates through two steps. In the first, denoted E-step, an estimate is obtained for the 301 signature exposures, E, given the current parameter guess, S (k) . In the subsequent M-step, E is 302 used to update the parameter estimate for the next iteration, S (k+1) . Iteration through these 303 steps finishes when the likelihood of the observed data, p(M|S), converges to a local 304
maximum. 305
The data likelihoods obtained for different values of N are compared in order to 306 determine the number of mutational processes involved. Because increasing N normally leads 307 to a better explanation of the data, due to the higher number of available model parameters,the likelihood generally rises with N. Overfitting of the data is avoided applying the Bayesian 309 information criterion (BIC) [68] , a model selection criterion whose second term corrects for 310 the model complexity: 311
The BIC is calculated for each of the models, and the one exhibiting the highest BIC 312 value is selected [68, 69] . After inference of signatures, EMu can estimate both the global 313 exposures in each genome and the local exposures per genomic region. Inference of local 314 exposures is performed by dividing each genome into non-overlapping segments of equal 315 length, and using the estimated global exposures as an informed prior distribution. The 316 patterns of variation in local exposures can subsequently be compared within and across 317
genomes. 318
It is worth noting that, while EMu builds upon a valid alternative interpretation of 319 NMF, which considers the latter as an application of EM to a particular problem [64], the 320 novel concepts and advantages of the method presented by Fischer et al. are not intrinsic 321
properties of the EM paradigm, but explicit enhancements that are amenable to assimilation 322 by other approaches. On the other hand, EMu suffers from the same sensitivity to initial 323 conditions as conventional NMF, and it may as well benefit from alternative initialisation 324 strategies. Despite this, EMu successfully exploits a probabilistic formulation of mutational 325 signature inference to address previously unexplored aspects, namely the incorporation of 326 context-and tumour-specific opportunity for mutations, the estimation of local signature 327 exposures, and the direct determination of the number of mutational processes. 328
As noted above, the WTSI Framework has been criticised for requiring a manual selection of 331 the number of mutational signatures, N, on the basis of heuristics that are indicative of the 332 goodness of the solutions. While EMu addresses this issue by means of a purely probabilistic 333 methodology, alternative approaches have proceeded by wrapping NMF in a Bayesian
The BayesNMF software by Kasar et Fischer et al. [61] , BayesNMF exploits the compatibilities between NMF and a Poisson 338 generative model of mutations. More specifically, the number of mutations of the k-th type in 339 a genome g, m kg , is assumed to be the combination of N independent mutation burdens, m kg n 340 (with 1 ≤ n ≤ N); such burdens are in turn assumed to be generated by a Poisson process 341 parameterised by mutation-type-and genome-specific rates, such that the expected number of 342 mutations attributed to signature S n is: 343
The properties of the Poisson process [73] then imply that m kg is also Poisson-344 distributed as: 345
Consequently, as already seen, the estimation of signatures (S) and exposures (E) by 346 genome. The iterative fitting algorithm, which is applied separately to each catalogue, starts 500 by discarding those signatures in which a mutation type that is absent from the examined 501 catalogue has a probability above 0.2. This prevents consideration of signatures that, 502 according to their mutational profiles, are unlikely to be present in the tumour. An initial 503 signature is then selected, such that the sum of squared errors (SSE) between the signature 504 and the mutational profile of the catalogue is minimised. The exposure value that minimises 505 the SSE for the chosen signature is set as the only positive exposure. In successive iterations, 506 each of the remaining signatures is evaluated to find the exposure value that minimises the 507 SSE between the reconstructed profile (including the previously incorporated exposures and 508 the candidate one) and the mutational profile of the tumour. The signature achieving 509 minimum SSE is selected, and its optimal exposure is incorporated to the reconstructed 510 profile. The process continues until the difference in SSE before and after an iteration falls 511 below an empirically determined threshold of 10 -4 ; the estimated exposures are then 512 transformed to proportions. Finally, any exposure lower than 0.06 (6%) is discarded, in order 513 to exclude spurious signatures; this minimum exposure threshold was also empirically 514 determined from simulation studies. 515
An iterative regression strategy has important associated risks, the most prominent 516 being the impossibility of reducing or removing the contribution of a signature after it has 517 been selected. Consequently, a signature that is actually absent from the sample might be 518 unalterably chosen in the initial iterations, only because it fits the overall profile of the tumourbetter than any other signature. This is not a rare situation, since one-third of the currently 520 published mutational signatures [31] (all of which are by default included in S) are mostly 521 composed of cytosine-to-thymine (C>T) changes. Thus, for example, a mutational profile 522 arising from the combination of two given signatures may initially be best fitted by a third 523 signature which does not actually contribute to the mutational profile, but which significantly 524 resembles it. Two measures to minimise the risk of misfitting are: (a) carefully selecting the 525 signatures to include in S, preferring those that have been already associated with the 526 examined tumour type; and (b) considering knowledge about additional genomic features 527 linked to the activity of a mutational signature in a genome. Limiting the set of candidate 528 signatures also lessens the risk of overfitting, especially given that the number of signatures, 529 N, is indirectly determined in this method through the empirically set thresholds for change in 530 SSE and minimum exposure value. On the other hand, the described measures increase the 531 opportunity for the biases of the investigator to influence the outcome. targeted therapies that may benefit some subgroups on the basis of the molecular mechanisms 572 involved [19, 22, 24, 27, 91] ; (c) to discover or support causative links between exposure toknown or novel carcinogens and the development of particular cancer types, by determining 574 the extent to which those carcinogens contribute to mutagenesis [25, 26, 92, 93] ; (d) to evaluate 575 the safety of chemotherapeutic agents, some of which have been shown to contribute to the 576 mutation burdens in exposed patients, with a view toward minimising the mutagenic impact 577 of novel therapies, especially in relation to potential resistant clones [19, 20] ; (e) to drive 578 novel molecular research directed at establishing links between mutagens or molecular 579 processes and currently unexplained ('orphan') signatures [19] , or to tease apart the 580 individual fingerprints hidden in composite mutational patterns, such as that of the complex 581 From a biological standpoint, the potential of mutational signature analysis to identify 588 and quantify the contributions of mutagenic processes operative in cancer genomes makes it 589 an outstanding tool for further delving into the fundamental causes and mechanisms of 590 tumorigenesis [7, 93] . For instance, by contrasting the mutational mechanisms that operate in 591 normal and cancer genomes, the study of signatures has helped to settle the long-standing 592 debate around whether the mutation rates and processes shaping the genomes of normal cells 593 can account for the aberrations found in cancer genomes [23, 95] . Another example is the 594 study of mutational processes affecting both cancer and normal cells, some of which are 595 associated with biological age [28, 96] . The identification of mutational signatures in cancer genomes remains a daunting 616 endeavour, despite the breakthroughs it has spurred. In the short term, some of the 617 computational strategies reported here will likely be subjected to significant refinement, or 618 extended through the release of new software, while fresh approaches to signature discovery, 619 using yet-unexploited techniques, are also sure to arrive. In the longer term, it must be noted 620 that current methods base their signature models exclusively on mutational profiles, and fail 621 to incorporate other experimental and clinical knowledge about mutational processes. Instead, 622 current studies rely on a manual, informal consideration of the additional biological features 623 associated with certain signatures. Such features should be quantified and formally 624 accommodated in mathematical models, if methods for identification are to be further 625 sharpened. At the same time, the pursuit of high-resolution mutational signatures by 626 accounting for additional contextual features might be hindered by the limitations of currentmodels. It can be argued that innovative models assuming niether complete mutual 628 independence nor non-independence between the features of a signature could prove key to 629 achieving the ideal compromise between flexibility and complexity that is warranted for 630 powerful, stable and accurate delineation of mutational signatures. 631
As current and forthcoming approaches shed light on the mathematical properties of 632 mutational signature discovery, the study of somatic mutation patterns will surely be extended 633 through the addition of new signatures, aberration classes, contextual features, and previously 634 unexamined cancer types. Meanwhile, the insights yielded by advances in this field will 635 further our understanding of the causes, mechanisms and evolution of human malignancy, and 636 provide new opportunities for cancer prevention and treatment. 637
• The somatic mutations in a genome are the result of the activity of one or more 640 mutational processes, some of which imprint a distinct mutational signature. 641
• Nonnegative matrix factorization (NMF) is the most widely used method for 642 identifying mutational signatures. 643
• Alternative approaches include partly and fully probabilistic models, as well as NMF 644 implementations offering greater ease of use. 645
• The study of mutational signatures can prove useful for cancer prevention and 646 treatment efforts, including patient stratification and identification of novel mutagens. 647
• The field will likely be expanded with the inclusion of additional techniques, mutation 648 classes, biological features and tumour types. 649 
